Fosamprenavir and Nelfinavir Mesylate

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with nelfinavir may increase the plasma concentrations of amprenavir. The mechanism is nelfinavir inhibition of amprenavir metabolism via CYP450 3A4. In 6 study subjects, coadministration of nelfinavir (750 mg three times a day) and amprenavir (750 or 800 mg three times a day) for 2 weeks resulted in a 14% decrease in amprenavir peak plasma concentration (Cmax) but a 189% increase in its trough plasma concentration (Cmin) compared to administration of amprenavir alone. Overall systemic exposure (AUC) was unchanged. The clinical significance of these findings is unknown. Patients receiving amprenavir or fosamprenavir with nelfinavir should be monitored for potentially increased side effects of both drugs. Appropriate dosages of the drugs in combination with respect to safety and efficacy have not been established.

Fosamprenavir

Generic Name: fosamprenavir

Brand name: Lexiva, Telzir

Synonyms: n.a.

What is Fosamprenavir?

Nelfinavir Mesylate

Generic Name: nelfinavir

Brand name: Viracept

Synonyms: Nelfinavir

What is Nelfinavir Mesylate?